Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ziagen
(United States) [Available]Synonyms :
ABC, abacavir
Class :
Antiviral Agents
Brand Name :
Ziagen
(United States) [Available]Synonyms :
ABC, abacavir
Class :
Antiviral Agents
Dosage Forms & StrengthsÂ
TabletÂ
300 mgÂ
Oral SolutionÂ
20 mg/mlÂ
300 mg oral tablet 2 times a day or 600 mg tablet orally daily
Dosage Forms & StrengthsÂ
TabletÂ
300 mgÂ
Oral SolutionÂ
20 mg/mlÂ
Infants >3 years to adolescents:
Dose instructions based on weight:
14 to <20kg: 150 mg orally twice daily
20 to <25 kg: 150 mg orally in the morning and 300 mg orally in the evening
>25 kg 300 mg orally every 12 hours
Refer to adult dosing
may decrease the therapeutic effect when combined
may diminish the rate of excretion leading to a higher serum level
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
it decreases the rate of elimination of pidotimod
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
may increase the risk of adverse effect of other reverse transcriptase inhibitors
reverse transcriptase inhibitors increase the concentration of ergonovine in the serum
may diminish the serum concentration of each other when combined
antiretroviral agents undergo intracellular phosphorylation that will reduce the efficacy of cladribine
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
The Therapeutic effectiveness of abacavir may be reduced by methadone
cefotiam might lead to a reduction in the rate of excretion of abacavir, potentially leading to elevated serum levels
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
aminophenazone has the potential to reduce the rate of excretion of abacavir, leading to an elevation in its concentration serum
abacavir Might lead to a reduction in the rate of excretion of triethylenetetramine, potentially leading to elevated levels of serum
meticrane has the potential to enhance the rate of excretion of abacavir; this can potentially lead to decreased levels of serum, possibly diminishing its effectiveness
abacavir has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
tinidazole has the potential to reduce the rate of excretion of abacavir, potentially leading to an elevation in level of serum
abacavir has the potential to reduce the excretion rate of deferiprone, leading to an increased level of serum
When abacavir is used together with paritaprevir, this leads to a reduction in the abacavir metabolism
the excretion rate of neomycin may be reduced with abacavir causing increased serum concentrations
the excretion rate of abacavir, when decreased by pralidoxime, results in increased serum level
an increase in serum level with a decreased excretion rate of almasilate is observed when used in combination with abacavir
diatrizoate may slow down the pace at which abacavir is excreted, potentially raising the serum level
flupirtine excretion rate may be slowed by abacavir, raising the possibility of higher serum levels
fentiazac may reduce the elimination rate of abacavir, resulting in a greater serum level
lonazolac may reduce the elimination rate of abacavir, resulting in a greater serum level
zomepirac may reduce the elimination rate of abacavir, resulting in a greater serum level
abacavir leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of abacavir which leads to increased level of serum
abacavir leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
abacavir leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
abacavir leads to a reduction in the rate of excretion of oxyquinoline, which leads to an increased level of serum
abacavir leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
abacavir leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
abacavir leads to a reduction in the rate of excretion of estrone sulfate, which leads to an increased level of serum
isoxicam might reduce the excretion rate of abacavir, leading to a potential elevation in serum levels
mycophenolic acid has the potential to reduce the excretion rate of abacavir, leading to a potential increase in serum levels
the excretion rate of sulbactam may be decreased by abacavir, potentially leading to a higher serum level
abacavir: it may decrease the excretion rate of abacavir CNS depressant
abacavir: it may decrease the excretion rate of abacavir CNS depressant
abacavir: it may decrease the excretion rate of abacavir CNS depressant
abacavir: it may decrease the excretion rate of abacavir CNS depressant
abacavir: it may decrease the excretion rate of abacavir CNS depressant
When abacavir is used together with adenine, this leads to a reduction in the abacavir's metabolism
the abacavir metabolism can be decreased when combined with fostamatinib
niflumic acid may lower the excretion rate of abacavir, which could result in a raised serum level
abacavir may diminish the excretion speed of inosine pranobex, potentially leading to an elevated serum level
it decreases the concentration of antiretroviral agent in the serum
may diminish the tiopronin excretion rate
excretion rate of abacavir, which leads to high-level serum concentration, is reduced when interacting with cefmetazole
the excretion rate of ribostamycin is reduced by abacavir, which results in higher serum concentration
the rate of excretion of aurothioglucose may be reduced with abacavir
gadopentetic acid could potentially decrease the excretion rate of abacavir, leading to a higher serum level
the excretion rate of ioxilan may be decreased by abacavir, potentially resulting in a higher serum level
the rate of excretion of inositol may be reduced
the rate of excretion of abacavir may be decreased
phylloquinone may reduce the excretion rate of abacavir, potentially leading to higher serum levels
muzolimine has the potential to enhance the excretion rate of abacavir, leading to a potential decrease in serum levels and a potential reduction in efficacy
the excretion rate of n-acetyl tyrosine may be reduced by abacavir, potentially leading to higher serum levels
lornoxicam: it may decrease the excretion rate of abacavir
the rate of excretion of potassium nitrate may be reduced
sulindac may lower the excretion rate of abacavir, potentially resulting in a raised serum level
the rate of excretion of topiroxostat may be reduced
the rate of decrease of abacavir may be reduced
the rate of decrease of abacavir may be reduced
the rate of excretion of abacavir may be reduced
the rate of excretion of abacavir may be reduced
the rate of excretion of abacavir may be reduced
the administration of clonixin may reduce the rate at which abacavir is excreted, potentially leading to an increase in serum levels
flunixin may lower the excretion rate of abacavir which could result in a raised serum level
tepoxalin may reduce the excretion rate of abacavir, potentially leading to elevated serum levels
the rate of excretion may be reduced
the rate of excretion of phosphoric acid may be decreased
abacavir may lessen the excretion speed of hydroxyethyl starch, potentially leading to an elevated serum level
choline magnesium trisalicylateÂ
choline magnesium trisalicylate may diminish the excretion rate of abacavir, potentially leading to an elevated serum level
abacavir might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
the activity of the anthrax vaccine can be reduced when used in combination with abacavir
the excretion rate may be decreased
Actions and Spectrum:Â
Phosphorylation of abacavir results in active metabolites that vie with one another to be incorporated into viral DNA. As a DNA synthesis chain terminator, they inhibit the HIV reverse transcriptase enzyme.
Frequency defined Â
>10%Â
Nausea (17-19%)Â
Fatigue (12%)Â
vomiting (10%)Â
1-10%Â
Musculoskeletal pain (5-7%)Â
Diarrhea (5-7%)Â
Black Box Warning:
The warnings may include serious potential effects on liver.
Contraindication / Caution:
Contraindication:
Hypersensitivity
Caution:
lactic acidosis
Pregnancy Warnings:
Pregnancy category: Not assigned
Lactation:
Excretion of the drug in human breast milk is unknown.Â
Pregnancy Categories:Â Â Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.  Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.  Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.  Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.  Â
Category N: There is no data available for the drug under this category.  Â
Pharmacology:Â
Abacavir drug also used in combination with other antiviral drugs to decrease the rate with which an HIV infection progresses.Â
Pharmacodynamics:Â
Phosphorylation of abacavir results in active metabolites that vie with one another to be incorporated into viral DNA. As a DNA synthesis chain terminator, they inhibit the HIV reverse transcriptase enzyme.
Pharmacokinetics:
Absorption Â
Quick oral absorptionÂ
83 percent bioavailability mcg/mL (300 mg); 4.26 mcg/mL (600 mg) was the peak plasma concentration.
DistributionÂ
The volume of distribution is 0.86 L/kg and plasma protein bounding is 50%Â
MetabolismÂ
The drug undergoes hepatic metabolism through liver enzymes like glucuronidation and alcohol dehydrogenase into glucuronide metabolites and inactive carboxylate.Â
Elimination and excretionÂ
The drug excreted 16% through Feces and 80% through urine. Half-Life: 1 ½ hoursÂ
Administration:Â
Abacavir is taken as tablet/oral solution with or without food.Â
The drug should be taken only on medical advice.Â
Patient information leafletÂ
Generic Name: abacavir
Why do we use abacavir?Â
Abacavir has the Anti-viral properties which is a nucleoside reverse transcriptase inhibitor (NRTI). This drug helps in preventing viral proliferation. It is available in the form of combination with other antiviral drugs.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
